Lupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by India's DCGI for treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS.